The present invention provides an article designed to deliver a composition to the vaginal, oral, nasal and/or rectal cavity and a method for manufacturing the article. The article exploits and/or protects the highly vascularized nature of the vaginal, oral, nasal and rectal mucosal tissue to deliver compositions to localized areas.
The vaginal, oral, nasal and rectal cavities provide a potential pathway for infection and disease to enter the body due to the copious blood supply in these regions and the lack of the stratum corneum that protects exposed surface skin.
The vaginal delivery route is known to be useful for the delivery of pharmaceutical agents that have their site of action within tissues or organs close to the vagina, in particular, for administration to the vaginal tissues.
Devices for the delivery of pharmaceutical agents and other compositions into the body cavities are known. Such devices are either of the type where a medicament is impregnated into the device, or of the type that carries an encapsulated medicament.
U.S. Pat. No. 7,004,171 and published PCT Appl. No. WO 2003/070216 disclose a transvaginal drug delivery system comprising: (a) a deposition comprising an effective amount of the drug and, optionally, a wetting agent; and (b) a polymeric support on which the deposition is deposited.
U.S. Pat. No. 7,341,737 discloses a tampon adapted to deliver a therapeutic agent, the tampon including a tampon body having a distal end; and a dosage form affixed to the distal end of the tampon body, wherein the dosage form includes a formulation including a therapeutic agent, and wherein the dosage form comprises a plurality of layers. Also, a method for manufacturing a medicated tampon adapted to deliver a therapeutic agent, the method including manufacturing a tampon body having a distal end; producing a dosage form having a plurality of layers, wherein the dosage form includes a formulation including a therapeutic agent; and affixing the dosage form to the distal end of the tampon body.
Brown-Skrobot, U.S. Pat. No. 5,679,369, discloses additives to tampons to inhibit the production of toxic shock syndrome toxin-1. The additives generally are not liquid at or near room temperature, and therefore, they require a carrier material, such as isopropyl alcohol. This is representative of the delivery of an agent that acts to inhibit the growth of infections and/or disease in the body cavity.
In practice several problems are inherent in a process that attempts to introduce a composition into or onto an absorbent material or cover material of the article by coating, dipping, solidifying, or the like. Procedures such as these that may work in a laboratory setting may be precluded from application to an automated manufacturing process.
For example during manufacture of a tampon associated with active additives, where careful dosing is one of requirements, the active additive and its carrier must be maintained in a solution that is both homogeneous and at a proper concentration and purity. These requirements are difficult to accomplish during normal operation, and are significantly more difficult to maintain when the tampon machine stops. In addition, tampons of different densities may absorb an applied active additive composition differently, resulting in variability in agent absorption into the tampons across different tampons.
Specifically, the requirement to provide constant agitation or mixing of the ingredients to the excipient and active compounds raises concerns as to how to keep the composition homogeneous when the manufacturing equipment stops during normal operation cycling. The use of inline mixers and recirculation of the heated therapeutic and excipient contained liquid compounds during machine stops may provide a method to keep the solution moving and mixed. However, because a machine could be stopped for several hours, the stability of some compound mixtures may be compromised by long durations at elevated temperatures, or by mechanical shear forces due to the continuous pumping of the recirculating solution also it runs into lot of machine maintenance related problems, to overcome this issue there is a need of an efficient method to incorporate a composition in to an article.
We have found an improved method to incorporate compositions in articles of manufacture useful to deliver a composition to the vaginal, oral, nasal and/or rectal cavity.
We have discovered that associating the composition with at least one carrier that is then incorporated into the article overcomes many of the processing concerns of the prior art.
In one embodiment of the invention, an article suitable for insertion into a body cavity includes a first structure, a cover substantially containing the first structure, and a waxy composition associated with at least one carrier that is also substantially contained by the cover. The first structure is arranged and configured to fit into a body cavity. The cover is substantially liquid permeable material. The waxy composition comprises a compound or combination of compounds selected from the group consisting of;
In an alternative embodiment of the invention a method of making an article suitable for insertion into a body cavity includes the steps of: (a) applying a waxy composition to at least one carrier; (b) providing a first structure arranged and configured to fit into a body cavity; and (c) substantially enclosing the first structure and the at least one carrier within an cover of material comprising a liquid permeable material. The waxy composition comprises a compound or combination of compounds selected from the group consisting of:
Examples of embodiments of the present invention will now be described with reference to the drawings, in which:
The invention as described herein will be described for exemplary purposes using a tampon as an example of an article that is designed to fit into vaginal cavity to deliver a composition such as an active ingredient to the vagina. The invention, however, applies in a similar way to deliver compositions to or through the tissue of other body cavities like oral, nasal and rectal and hence invention should not be limited to the example described herein. The shape or dimensions of products may vary depending upon the anatomy of body cavity so as to give maximum benefits and comfort.
As used herein the term “first structure” may comprise absorbent and/or non-absorbent material. The absorbent material may consist of, but is not limited to, cellulose or cellulose derivative fibres, cotton, starch, rayon, sponge, woodpulp, polyolefin, polyester, polyamide, polyurethane, cross-linked carboxymethylcellulose, acrylic acid, methacrylic acid, 2-acrylamido-2-methyl propane sulphonic acid or a mixture thereof, or a hydrogel.
Waxy materials tend to be somewhat tacky, and difficulties arise in particular with regard to the handling of sheets coated or impregnated with such waxy materials during their production. The sheet and its waxy material tend to stick to machine parts and to foul the machinery with consequent process.
The non-absorbent material may be partially or completely non-absorbent or may have only a small degree of absorbency. More preferably the non-absorbent material is made up of, but is not limited to, polyester, polypropylene, polyethylene, aramid, nylon, acrylic, synthetic fibers, bicomponent or mixtures thereof.
As used herein the term “liquid-permeable” and variants thereof indicates that liquids, such as water or bodily fluids, are able to pass through a cover.
The liquid-permeable cover can be formed from woven or nonwoven materials having a porous substrate. The woven and nonwoven materials are well known in literature and would be readily understood by persons skilled in the art that any such liquid-permeable cover may be applied or used to deliver the present invention. The liquid-permeable cover can be formed from a non-porous materials having previously been processed into an apertured film. The aperturing processes are well known in literature and would be readily understood by persons skilled in the art such that any such liquid-permeable cover may be applied or used to deliver the present invention.
In one preferred embodiment, the composition is a waxy composition selected from the group consisting of;
The fatty acid portion of the said monoesters and diesters may be derived from caprylic, capric, lauric, myristic, palmitic and stearic acids, which are saturated fatty acids whose chain lengths, respectively, are C8, C10, C12, C14, C16 and C18. The fatty acid portion of the aforementioned monoesters and diesters may be derived as well from unsaturated fatty acids having carbon chain lengths also ranging from C8 to C18, one example of such unsaturated fatty acids being oleic acid. The preferred fatty acid for use in the practice of the present invention is lauric acid, a saturated fatty acid whose chemical formula is C11H23COOH.
As used in this specification and the appended claims, the term “aliphatic” has the meaning usually accorded it in organic chemistry, i.e. “aliphatic” refers to organic compounds characterized by straight- or branched-chain arrangement of the constituent carbon atoms.
As used in this specification and the appended claims, the term “polyhydric” refers to the presence in a chemical compound of at least two hydroxyl (OH) groups. Thus, a polyhydric aliphatic alcohol is one which has at least two hydroxyl groups and in which the carbon backbone is either straight or branched.
Polyhydric alcohols suitable for forming monoesters and/or diesters for use in the practice of the present invention are 1,2-ethanediol; 1,2,3-propanetriol (glycerol); 1,3-propanediol; 1,4-butanediol; 1,2,4-butanetriol and the like. The preferred polyhydric aliphatic alcohol for forming monoesters and diesters for use in the practice of the present invention is 1,2,3-propanetriol (commonly called glycerol) whose formula is HOCH2CH(OH)CH2OH.
The monoester of glycerol and one of the designated fatty acids may be used in the practice of the present invention because that ester will have two hydroxyl groups associated therewith which are derived from the glycerol. The diester of glycerol and one of the designated fatty acids may also be used because that ester will have one hydroxyl group associated therewith which is derived from the aliphatic alcohol glycerol. Indeed, as will be seen hereinafter, blends of glycerol monolaurate and glycerol dilaurate have been found to be useful in the practice of the present invention. Preferred esters for use in the practice of the present invention are glyceryl monolaurate, glyceryl dilaurate and mixtures thereof.
Referring to the drawings in greater detail,
As seen in the Figures, article 10, generally includes a first structure 20, a cover 30 and an active ingredient associated with carrier 50. Article 10, can have a front-end portion 13 for insertion of the article 10 into body cavity, a center portion 14, and a rear-end portion 15 for gripping or withdrawing the article 10. First structure 20, can be in the form of a roll, e.g., wound about a center portion of a fibrous sliver as shown in
First structure 20, comprises an outer surface 21 and an inner surface 22, with an front end portion 23 aligned with front-end portion 13, center portion 24 aligned with center portion 14, and rear portion 25 aligned with rear-end portion 15 of the article 10.
First structure 20 is substantially enclosed with a cover 30, comprising an inner surface 32 facing the outer surface 21 of the first structure 20, and an outer surface 31 facing the body cavity. An active ingredient 40 associated with carrier 50, is substantially positioned within the article.
As can be seen in
As best seen in
As seen figures article 10 of the present invention is an elongated fibrous structure comprising a cylindrical, spherical or ellipsoid shape, for simplicity in understanding the dimension of article 10,
In general, the method of making an article of the present invention is typically divided in two steps;
Step 1: The selected composition to be applied may be dissolved in a suitable diluent to form a liquid mixture that is uniformly applied, to a carrier. The diluent may be driven off (e.g., a volatile solvent), or if desired may remain as part of the coating composition. The carrier coated with the selected composition may be rolled up or otherwise stored until desired for processing into an article of manufacture.
Step 2: In one embodiment, illustrated in
In an alternate embodiment shown in
Number | Date | Country | |
---|---|---|---|
61116656 | Nov 2008 | US |